-
Annual Report Planning | More than 30% of Pharmaceutical Stocks on the Science and Technology Innovation Board's R&D Expenses Decline, with Anxu Biotechnology and Jindik's Stocks Cutting Back
The Science and Technology Innovation Board has become a gathering place for "hard technology" pharmaceutical enterprises. With the release of annual reports from relevant enterprises, there is also ...- Ty奇葩罗牛山831
- 2024-5-12 20:02
- 支持
- 反对
- 回复
- 收藏